



Emerging Influenza Viruses and Anti-influenza Vaccines

Guest Editors:

Dr. Pavel Volchkov

The National Medical Research
Center for Endocrinology, 117036
Moscow, Russia

Dr. Irina Isakova-Sivak

Department of Virology, Institute
of Experimental Medicine, 12
Acad. Pavlov Street, St
Petersburg, Russia

Deadline for manuscript
submissions:
closed (30 October 2023)

Message from the Guest Editors

Avian influenza is a highly contagious viral disease that affects various livestock, domestic, and wild animals. Outbreaks of avian influenza occur regularly on poultry farms around the world. The only way to contain the epidemic is to slaughter the entire poultry population that has come into contact with infected animals, resulting in severe economic losses. On the other hand, the greatest danger is that animal influenza viruses will be transmitted to humans. In this case, the appearance of a disease with unpredictable symptoms is possible.

It should be noted that the recent pandemic caused by another disease of zoonotic origin that started to spread from human to human—COVID-19—has clearly shown the need to find new ways to develop effective vaccines. As a result, new approaches to vaccine production have been actively developed. At the same time, it is generally accepted that influenza viruses pose a pandemic threat, which requires the development of effective ways to prevent infection.

This Special Issue will bring together original research papers or reviews dealing with research into emerging influenza viruses and new approaches to influenza prevention.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)